Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1532-5415.2010.02994.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design, synthesis and biological evaluation of bisnoralcohol derivatives as novel IRF4 inhibitors for the treatment of multiple myeloma.
Eur J Med Chem
January 2025
Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, China. Electronic address:
Interferon regulatory factor 4 (IRF4) is specifically overexpressed in multiple myeloma (MM) and mediates MM progression and survival, making it an emerging target for MM treatment. However, no chemical entity with a defined structure capable of directly binding to and inhibiting IRF4 has been reported. We screened our small library of steroid analogs and identified bisnoralcohol (BA) derivative 18 as a novel hit compound capable of inhibiting IRF4, with an IC of 13.
View Article and Find Full Text PDFCharacterizing sexuality and assessing predictors of sexual satisfaction in patients with multiple myeloma and other hematological cancers.
Support Care Cancer
January 2025
Department of Psychology, University of Calgary, Calgary, AB, Canada.
Purpose: Existing studies documenting cancer-related sexual concerns among hematological cancer patients tend to group all types of hematological cancer together, overlooking potentially unique concerns associated with multiple myeloma (MM). This study is the first to characterize sexuality in MM and to examine predictors of sexual satisfaction for MM, comparatively with participants with other hematological cancer types.
Methods: We conducted a cross-sectional self-report survey-based study.
Outcomes of Older Adults and Frail Patients Receiving Idecabtagene Vicleucel: A CIBMTR Study.
Blood Adv
December 2024
H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
Idecabtagene vicleucel (ide-cel) is an anti-BCMA CAR-T cell therapy approved for patients with relapsed/refractory multiple myeloma (RRMM) after 2 prior lines of therapy. There is limited data on outcomes of CAR T in older adults and frail patients with RRMM. In this study, we utilized data from the Center for International Blood and Marrow Transplantation Registry to describe the safety and efficacy of ide-cel in these clinically important subgroups.
View Article and Find Full Text PDFLong Term Follow up of Total Therapy IV: A Phase III Clinical Trial for Standard Risk Multiple Myeloma.
Blood Adv
December 2024
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!